Figure 5.

CD28 co-stimulatory signals modulate the effects of agonistic anti-TNFRSF mAbs in vivo. WT C57BL/6 mice were treated with either agonistic anti-GITR, anti-OX40, anti-4-1BB alone (250 μg/dose; i.p.) or together with anti-CD28 dAb (100 μg/dose; i.p.) every other d for six d and splenocytes were harvested on d 8. (A) Representative plots of Ly-6C versus Ki-67 expression on CD4⁺Foxp3⁺ Tregs. (B) Absolute number of splenic CD4⁺Foxp3⁺ T cells on d 8 after antibody treatment. (C) Representative plots of Ki-67 expression on CD4⁺Foxp3⁻CD44⁺CD62L⁻ MP T cells after antibody treatment on d 8. (D) Absolute number of CD4⁺ MP T cells after antibody treatment. (E) Representative plot of Ki-67 expression on CD8⁺ CM T cells. (F) Absolute number of CD8⁺ CM T cells after antibody treatments. (G) Representative plot of Ki-67⁺ expresson on CD8⁺ EM T cells. (H) Absolute number of CD8⁺ EM T cells after antibody treatment. (A-H) represent the result of one experiment of two using five mice per group.